Reuters logo
3 个月前
BRIEF-Chiasma reports Q1 loss per share $0.29
2017年5月5日 / 中午12点12分 / 3 个月前

BRIEF-Chiasma reports Q1 loss per share $0.29

1 分钟阅读

May 5 (Reuters) - Chiasma Inc:

* Chiasma reports first quarter 2017 results

* Q1 loss per share $0.29

* Chiasma Inc - following receipt of crl for octreotide capsules NDA, company participated in an end of review meeting with FDA

* Chiasma Inc - FDA "reiterated its strong preference" for a randomized, double-blind and controlled trial for octreotide capsules

* Chiasma Inc - for octreotide capsules, FDA suggested that some of its concerns could potentially be addressed through placebo-controlled study design

* Chiasma Inc - FDA advised in CRL that, during a site inspection, certain deficiencies were conveyed to representative of one of Chiasma's suppliers

* Chiasma Inc - in December 2016, supplier informed chiasma that it had received its establishment inspection report from FDA

* Chiasma Inc - expects its existing cash, cash equivalents and marketable securities to fund operations beyond 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below